Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome

Fertility and Sterility

Volumn 94, Issue 1, 2010, Pages 236-241

  Kim, Chung Hoon ^a   Jeon, Gyun Ho ^a   Kim, So Ra ^a   Kim, Sung Hoon ^a   Chae, Hee Dong ^a   Kang, Byung Moon ^a  

^a University of Ulsan   (South Korea)

Author keywords

Intraovarian stromal blood flow; IVF; ovarian stimulation; PCOS; pioglitazone

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; DIANE; ESTRADIOL; PIOGLITAZONE; PLACEBO; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OOCYTE MATURATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY BLOOD FLOW; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; FEMALE; FERTILIZATION IN VITRO; FOLLOW-UP STUDIES; HUMANS; OVARY; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; STROMAL CELLS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952742502     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.02.029     Document Type: Article

References (36)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
3. Richardson M.R. Current perspectives in polycystic ovary syndrome. Am Fam Physician 68 (2003) 697-704
4. Baillargeon J.P., Iuorno M.J., and Nestler J.E. Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 9 (2002) 303-311
5. Iuorno M.J., and Nestler J.E. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 28 (2001) 153-164
6. De Leo V., la Marca A., Ditto A., Morgante G., and Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 72 (1999) 282-285
7. Nestler J.E., Jakubowicz D.J., Evans W.S., and Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338 (1998) 1876-1880
8. Cataldo N.A., Abbasi F., McLaughlin T.L., Lamendola C., and Reaven G.M. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 76 (2001) 1057-1059
9. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (2003) 951-953
10. Romualdi D., Guido M., Ciampelli M., Giuliani M., Leoni F., Perri C., et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 18 (2003) 1210-1218
11. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 23 (2008) 462-477
12. Homburg R., and Howles C.M. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 5 (1999) 493-499
13. Ghazeeri G., Kutteh W.H., Bryer-Ash M., Haas D., and Ke R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79 (2003) 562-566
14. Guzick D.S. Ovulation induction management of PCOS. Clin Obstet Gynecol 50 (2007) 255-267
15. Vandermolen D.T., Ratts V.S., Evans W.S., Stovall D.W., Kauma S.W., and Nestler J.E. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75 (2001) 310-315
16. Legro R.S., Barnhart H.X., Schlaff W.D., Carr B.R., Diamond M.P., Carson S.A., et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356 (2007) 551-566
17. Zaidi J., Campbell S., Pittrof R., Kyei-Mensah A., Shaker A., Jacobs H.S., et al. Ovarian stromal blood flow in women with polycystic ovaries-a possible new marker for diagnosis?. Hum Reprod 10 (1995) 1992-1996
18. Battaglia C., Artini P.G., Genazzani A.D., Gremigni R., Salvatori M., Sgherzi M.R., et al. Color Doppler analysis in oligo- and amenorrheic women with polycystic ovary syndrome. Gynecol Endocrinol 11 (1997) 105-110
19. Zaidi J., Jacobs H., Campbell S., and Tan S.L. Blood flow changes in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate: correlation with serum hormone concentrations. Ultrasound Obstet Gynecol 12 (1998) 188-196
20. Ehrmann D.A., Cavaghan M.K., Imperial J., Sturis J., Rosenfield R.L., and Polonsky K.S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 524-530
21. Pagano G., Tagliaferro V., Carta Q., Caselle M.T., Bozzo C., Vitelli F., et al. Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia 24 (1983) 351-354
22. Alivanis P., Giannikouris I., Paliuras C., Arvanitis A., Volanaki M., and Zervos A. Metformin-associated lactic acidosis treated with continuous renal replacement therapy. Clin Ther 28 (2006) 396-400
23. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100 (1997) 3149-3153
24. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 (1995) 12953-12956
25. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fereshetian A.G., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
26. Graham D.J., Green L., Senior J.R., and Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 114 (2003) 299-306
27. Hasegawa I., Murakawa H., Suzuki M., Yamamoto Y., Kurabayashi T., and Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 71 (1999) 323-327
28. Glueck C.J., Moreira A., Goldenberg N., Sieve L., and Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 18 (2003) 1618-1625
29. Brettenthaler N., De Geyter C., Huber P.R., and Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 3835-3840
30. Ortega-Gonzalez C., Luna S., Hernandez L., Crespo G., Aguayo P., Arteaga-Troncoso G., et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1360-1365
31. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
32. Ishibashi M., Egashira K., Hiasa K., Inoue S., Ni W., Zhao Q., et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40 (2002) 687-693
33. Stout D.L., and Fugate S.E. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 25 (2005) 244-252
34. Erdmann E., Charbonnel B., Wilcox R., Skene A.M., Massi-Benedetti M., Yates J., et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease. Diabetes Care 30 (2007) 2773-2778
35. Dolz M., Osborne N.G., Blanes J., Raga F., Abad-Velasco L., Villalobos A., et al. Polycystic ovarian syndrome: assessment with color Doppler angiography and three-dimensional ultrasonography. J Ultrasound Med 18 (1999) 303-313
36. Agrawal R., Sladkevicius P., Engmann L., Conway G.S., Payne N.N., Bekis J., et al. Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Hum Reprod 13 (1998) 651-655